Difference between revisions of "Bexarotene (Targretin)"
m (Text replacement - "[[Media:" to "[[File:") |
|||
Line 1: | Line 1: | ||
==General information== | ==General information== | ||
− | Class/mechanism: Retinoid, selectively binds and activates retinoid X receptor subtypes (RXRα, RXRβ, RXRγ), which allow them to function as transcription factors that regulate the expression of genes that control cellular differentiation and proliferation. Bexarotene inhibits the growth in vitro of some tumor cell lines of hematopoietic and squamous cell origin. Exact mechanism of action in the treatment of cutaneous T-cell lymphoma (CTCL) is unknown.<ref name="insert">[http://targretin.com/pdf/CAPS-PI-Jan18.pdf Bexarotene (Targretin) capsules package insert]</ref><ref>[[ | + | Class/mechanism: Retinoid, selectively binds and activates retinoid X receptor subtypes (RXRα, RXRβ, RXRγ), which allow them to function as transcription factors that regulate the expression of genes that control cellular differentiation and proliferation. Bexarotene inhibits the growth in vitro of some tumor cell lines of hematopoietic and squamous cell origin. Exact mechanism of action in the treatment of cutaneous T-cell lymphoma (CTCL) is unknown.<ref name="insert">[http://targretin.com/pdf/CAPS-PI-Jan18.pdf Bexarotene (Targretin) capsules package insert]</ref><ref>[[File:Bexarotene.pdf | Bexarotene (Targretin) capsules package insert (locally hosted backup)]]</ref><ref name="insert_gel">[http://targretin.com/pdf/GEL-PI-Jan-18.pdf Bexarotene (Targretin) gel package insert]</ref><ref>[[File:Bexarotenegel.pdf | Bexarotene (Targretin) gel package insert (locally hosted backup)]]</ref><ref>[http://targretin.com/ Targretin manufacturer's website]</ref> |
<br>Route: PO, topical | <br>Route: PO, topical | ||
<br>Extravasation: n/a | <br>Extravasation: n/a |
Revision as of 23:44, 19 September 2021
General information
Class/mechanism: Retinoid, selectively binds and activates retinoid X receptor subtypes (RXRα, RXRβ, RXRγ), which allow them to function as transcription factors that regulate the expression of genes that control cellular differentiation and proliferation. Bexarotene inhibits the growth in vitro of some tumor cell lines of hematopoietic and squamous cell origin. Exact mechanism of action in the treatment of cutaneous T-cell lymphoma (CTCL) is unknown.[1][2][3][4][5]
Route: PO, topical
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape,UpToDate (courtesy of Lexicomp), or the prescribing information.[1][3]
Diseases for which it is used
Patient drug information
- Bexarotene (Targretin) capsules package insert[1]
- Bexarotene (Targretin) gel package insert[3]
- Bexarotene systemic (Targretin) patient drug information (Chemocare)[6]
- Bexarotene systemic (Targretin) patient drug information (UpToDate)[7]
- Bexarotene topical (Targretin) patient drug information (UpToDate)[8]
History of changes in FDA indication
- 12/29/1999: Initial FDA approval "for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy."
Also known as
- Code name: LGD1069
- Brand names: Bexgratin, Targretin
References
- ↑ 1.0 1.1 1.2 Bexarotene (Targretin) capsules package insert
- ↑ File:Bexarotene.pdf
- ↑ 3.0 3.1 3.2 Bexarotene (Targretin) gel package insert
- ↑ File:Bexarotenegel.pdf
- ↑ Targretin manufacturer's website
- ↑ Bexarotene systemic (Targretin) patient drug information (Chemocare)
- ↑ Bexarotene systemic (Targretin) patient drug information (UpToDate)
- ↑ Bexarotene topical (Targretin) patient drug information (UpToDate)